ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences' U.S. Patent No. 11,970,746 (the '746 patent) unpatentable. This decision follows the PTAB's July 2025 Final Written. ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with s. ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of clinical evidence, the test has become a global standard-of-care by identifying patients who are – and are not – likely t. ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund focuses on long-term, competitively positioned companies that are well-managed and have significant potential in untapped markets. The letter also addressed the advancements in AI and how humans define themselves in the changing landscape. In Q4, the fund generated a return of 0.19% (Institutional Shares), underperforming the Russell 2 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Exelixis (EXEL) and Exact Sciences (EXAS) for potential value opportunities, with a closer examination needed to determine which stock offers better value [1] Valuation Metrics - Exelixis has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Exact Sciences, which has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for EXEL is 13.46, significantly lower than EXAS's forward P/E of 73.35, suggesting EXEL may be undervalued [5] - EXEL's PEG ratio is 0.69, while EXAS has a PEG ratio of 2.42, indicating that EXEL's expected earnings growth is more attractive relative to its price [5] - EXEL has a P/B ratio of 5.41 compared to EXAS's P/B of 7.76, further supporting EXEL's more favorable valuation metrics [6] Investment Conclusion - Given the stronger estimate revision activity and more attractive valuation metrics, EXEL is positioned as the superior option for value investors at this time [7]

Market Overview - U.S. equity markets in Q4 2025 were influenced by optimism regarding potential monetary easing and caution related to economic growth and valuations [1] - Early gains were attributed to strong AI-related earnings and a rate cut by the U.S. Federal Reserve in October, but sentiment cooled later due to mixed signals from the Fed [1] - Large-cap stocks rose 17.4% for the year and 2.4% in the quarter, while small caps gained 12.8% for the year and 2.2% in the quarter [1] - Value stocks outperformed growth stocks, returning 3.3% versus 1.2% for the quarter [1] Fund Performance - Meridian Growth Fund delivered a return of -0.39% (net) in the quarter, underperforming the Russell 2500 Growth Index's return of 0.33% [1] - The firm is monitoring factors affecting market returns, including potential changes in monetary policy and the sustainability of AI investments due to high valuations among hyperscalers [1] Company Spotlight: Exact Sciences Corporation - Exact Sciences Corporation (NASDAQ:EXAS) is recognized as a leading contributor to the Meridian Growth Fund, specializing in cancer screening and diagnostic test products [2][3] - As of January 26, 2026, Exact Sciences' stock closed at $102.51 per share, with a one-month return of 0.60% and an impressive 85.00% increase in value over the last 52 weeks [2] - The company has a market capitalization of $19.468 billion [2] - Exact Sciences is best known for its at-home colorectal cancer screening test, Cologuard, and saw stock performance improve due to signs of growth and the introduction of a new test [3] - The stock performance was further enhanced by Abbott's announcement to acquire Exact Sciences at a significant premium [3]

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter indicates a strong performance in the US equity market, with the S&P 500 rising by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter highlights a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - Exact Sciences Corporation (NASDAQ:EXAS) is noted for its cancer screening and diagnostic products, with a market capitalization of $19.453 billion [2] - The stock of Exact Sciences Corporation closed at $102.43 per share on January 16, 2026, with a one-month return of 0.60% and a remarkable 97.97% increase over the past 52 weeks [2] - The company is recognized for its Cologuard noninvasive colorectal cancer screening and has a pipeline that includes molecular residual disease (MRD) and multi-cancer early detection (MCED) testing [3] - Exact Sciences' stock saw positive contributions during the quarter following Abbott's announcement of a definitive all-cash acquisition agreement valued at approximately $21 billion, which provided a significant premium and drove the stock price higher [3]